Agree, Dalts. I joined the register in 2020, so therefore find...

Agree, Dalts. I joined the register in 2020, so therefore find it difficult to comment on Diamonds performance before that time; however, regardless of whether ANP could be in better or worse position than it currently stands, it was Diamond who also garnered the interest of CG (and I am sure he had stiff competition to win her over) and GP and steered the company to not only that position, but also toward the ATTL1102 phase 11b trial - which has facilitated the favourable position we now find the company in. I am sure Diamond was tired after 20 years in the seat (I would be) but yet he continued knowing ANP had something worth persevering with, regardless of the bashing he received from holders. I am new to bio-stocks, but with a background in science I do know it takes time to get the results and therefore understand that to some degree Diamond had his hands tied. He deserves respect for his work. Without it, I am sure we might not be here.